Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) was upgraded by investment analysts at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on Tuesday.
Several other analysts have also weighed in on ABEO. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Abeona Therapeutics in a report on Monday, November 25th. Cantor Fitzgerald reiterated an "overweight" rating and set a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.
Get Our Latest Research Report on Abeona Therapeutics
Abeona Therapeutics Stock Performance
Shares of NASDAQ ABEO traded down $0.04 during mid-day trading on Tuesday, hitting $5.57. The company had a trading volume of 203,401 shares, compared to its average volume of 408,963. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $9.01. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The firm has a market cap of $242.13 million, a P/E ratio of -2.07 and a beta of 1.44. The business's 50-day simple moving average is $6.04 and its 200-day simple moving average is $5.59.
Institutional Investors Weigh In On Abeona Therapeutics
Large investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in Abeona Therapeutics in the 3rd quarter valued at $84,000. Charles Schwab Investment Management Inc. bought a new stake in Abeona Therapeutics during the third quarter worth about $151,000. XTX Topco Ltd bought a new position in shares of Abeona Therapeutics in the third quarter valued at approximately $160,000. JPMorgan Chase & Co. grew its position in Abeona Therapeutics by 74.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company's stock worth $424,000 after acquiring an additional 28,606 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Abeona Therapeutics by 2.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock valued at $515,000 after purchasing an additional 2,434 shares in the last quarter. 80.56% of the stock is currently owned by institutional investors.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Read More
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
